Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets open firm
Tue, 16 Aug 09:30 am

Asian stock markets have opened the day on a firm note. Stock markets in Hong Kong (up 0.1%), South Korea (up 3.9%), Japan (up 0.3%) and Malaysia (up 0.3%) are leading the gains. However, markets in China are facing selling pressure (down 0.3%). The Indian stock market have opened the day on a firm note. Stocks in the technology and consumer durable space are leading the gains.

The BSE-Sensex is trading higher by around 150 points (0.9%) and the NSE-Nifty is up by around 41 points (0.8%). Midcap and small cap stocks are trading in the green as well, with the BSE-Midcap and BSE-Small cap indices up by 0.6% and 0.7% respectively. The rupee is trading at 45.24 to the US dollar.

FMCG stocks have opened the day on a firm note with Colgate, Palmolive, Dabur India, Marico and Nestle India leading the gains. Dabur is planning to venture into the Indian aroma products market. The company plans to expand the portfolio of its existing air freshener brand Odonil by launching a range of aroma products such as traditional oil burner, potpourri, pillar candle and aromatic floating candle. Presently, Odonil is available in block and room freshener spray formats and generates a sales turnover of Rs 1,250 m. Dabur aims to increase this to Rs 1,750 m in the financial year 2011-12. As far as the new product range is concerned, the company expects to achieve a sales target of Rs 3000 m by 2015. Currently, the air fragrances market in India is estimated to be about Rs 20 bn.

Pharma stocks have opened the day on a mixed note with Dr Reddy's Lab, Cipla and Piramal Healthcare in the green. However, Biocon and Ranbaxy Lab are facing selling pressure. Biotech major Biocon, has stated that the company is facing higher salary costs even for this year. The company expects the trend to escalate further and stabilise by next year. This phenomenon is not just due to an increase in poaching by its competitors but also from IT companies. The Chairman and MD of the company said that the company cannot be immune to this kind of market dynamics and expects to increase the salary costs for the year. In the financial year 2010-11, the standalone staff costs increased by 46% while the consolidated staff costs increased by about 27%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.